Comments
Cadila Healthcare (Zydus Cadila) on Friday informed that the company has received final approval from the US regulator, US Food and Drug Administration (USFDA) to market Budesonide Capsules in 3 mg (Enteric Coated).
The drug is a corticosteroid used for its anti-inflammatory action.
It will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Budesonide is $ 285.8 million (IMS MAT March 2017).
Cadila Healthcare shares gained by over 1 per cent to close at Rs 464 on National Stock Exchange (NSE) on Friday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.